Quick Facts

• Approved Use: May assist with a condition known as erectile dysfunction (ED).
• Additional Approved Use: May support management of pulmonary arterial hypertension (PAH) to improve exercise capacity.

---

Silagra (sildenafil citrate) is a prescribed therapy that addresses specific health conditions. The primary therapeutic use of this medication is to support the management of erectile dysfunction (ED) in men. This condition is characterized by a reduced ability to attain or maintain an erection suitable for sexual activity. When taken in the context of sexual arousal, the medication may help facilitate improved erectile function.

Additionally, sildenafil citrate is approved to treat pulmonary arterial hypertension (PAH). This involves high blood pressure affecting the arteries in the lungs and the right side of the heart. For individuals with PAH, therapy with sildenafil citrate is intended to improve the ability to engage in exercise and may contribute to delaying clinical worsening. This agent may be part of a comprehensive management plan as determined by a healthcare provider. It is important to note that this treatment does not represent a curative intervention for either condition.

Silagra (Sildenafil Citrate) is restricted to specific patient populations as defined by regulatory documents. Use is primarily established in adult men for the treatment of erectile dysfunction (ED) and in adult patients for pulmonary arterial hypertension (PAH).

The medicine is absolutely contraindicated for several groups. This includes all patients using any form of organic nitrates or nitric oxide donors, or those taking riociguat, due to the risk of severe blood pressure drop. It must not be used by patients with severe hepatic impairment or a recent history of stroke or myocardial infarction. Use is also prohibited in patients with resting hypotension (low blood pressure).

Age-related restrictions state the medicine is not indicated for women (for the ED use) or for individuals under 18 years of age (ED). Pediatric chronic use for PAH is officially not recommended. For patients over 65, and those with severe renal impairment or mild to moderate hepatic impairment, cautious use is required. The prescribing information advises regulators to consider a lower initial dose in these populations due to altered drug clearance.

Interactions with other medicines and products

Contraindicated Combinations

Nitrates and Nitric Oxide Donors: Sildenafil is contraindicated with all forms of nitrates and nitric oxide donors (e.g., nitroglycerin, isosorbide dinitrate, amyl nitrite) due to the significant risk of severe hypotension (dangerously low blood pressure) caused by potentiating the effects on the nitric oxide/cGMP pathway.

Guanylate Cyclase (GC) Stimulators: Co-administration with GC stimulators, such as riociguat, is also contraindicated due to the potential for symptomatic hypotension.

Use with Caution and Monitoring Required

Alpha-Blockers: Caution is required when sildenafil is co-administered with alpha-blockers. Patients should be hemodynamically stable on alpha-blocker therapy before initiating sildenafil, and treatment should begin with the lowest recommended dose to mitigate the risk of symptomatic hypotension.

CYP3A4 Inhibitors: Sildenafil is primarily metabolized by the cytochrome P450 3A4 (CYP3A4) enzyme. Strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, erythromycin) decrease the clearance of sildenafil, leading to increased plasma concentrations. Co-administration with ritonavir is not advised and carries a restriction on the maximum single dose to 25 mg within a 48-hour period. Starting with a lower dose is recommended when combining with other strong CYP3A4 inhibitors.

Other PDE5 Inhibitors: Use with other PDE5 inhibitors is generally not recommended.

Population Note: Caution is necessary in patients with bleeding disorders or active peptic ulceration.

The mechanism of action for Silagra (Sildenafil Citrate) is centered on the selective modulation of a specific molecular pathway that regulates vascular smooth muscle tone. The effect is amplification of the body's natural signaling process, not initiation.

---

1. Selective PDE5 Enzyme Inhibition

Silagra acts as a selective competitive inhibitor of Phosphodiesterase type 5 ( PDE5), an enzyme responsible for degrading the secondary messenger molecule cyclic Guanosine Monophosphate (cGMP). By blocking the PDE5 enzyme, the drug prevents the breakdown of cGMP, thereby stabilizing its concentration within the smooth muscle cells.

---

2. NO/cGMP Pathway Amplification

Sildenafil's mechanism is contingent upon the body naturally releasing Nitric Oxide ( NO), the signal that initiates cGMP production. The drug then amplifies this NO signal by protecting the newly formed cGMP from degradation. This cascade activates Protein Kinase G ( PKG), which is the molecule that directly mediates the downstream physiological effects on muscle cells.

---

3. Targeted Smooth Muscle Relaxation

The sustained cGMP- PKG pathway activity results in the physiological modulation of vascular smooth muscle, promoting relaxation (vasodilation) in specific peripheral vascular beds. This vascular change promotes increased localized blood flow to the target tissues, an outcome of the underlying NO/cGMP pathway modulation.

The administration of Sildenafil Citrate, the active ingredient in Silagra, follows two distinct protocols, differentiated by the approved indication. The primary route of administration is oral, delivered via a tablet, though an intravenous form is also approved for the pulmonary arterial hypertension (PAH) indication when oral use is not possible.

For the erectile dysfunction (ED) indication, the medicine is used as an intermittent regimen, taken only as needed. The usual starting oral dose is 50 mg, with the accepted range being 25 mg to 100 mg, but never more than once per day. This dose is typically taken approximately one hour prior to activity. The tablets may be taken with or without food, although a high-fat meal can delay the medicine’s absorption.

For the PAH indication, the medicine is used as a scheduled maintenance regimen. The standard oral dose is 20 mg, administered three times a day with doses spaced 4 to 6 hours apart. If a scheduled dose for PAH is missed, the protocol involves taking the dose as soon as remembered, but it is explicitly prohibited to take a double dose.

Specific population rules require consideration of a 25 mg initial oral dose for the ED regimen in older adults and patients with severe hepatic or renal impairment. Furthermore, the oral suspension form for PAH necessitates reconstitution with water and use of a calibrated dosing instrument.

Research Evidence / Overview of Studies for Silagra

---

Evidence Summary for Erectile Dysfunction (ED) Studies

Sildenafil Citrate was studied for its use in managing Erectile Dysfunction (ED), a condition marked by functional limitations. The primary research included numerous short-term, randomized, placebo-controlled trials (RCTs), typically lasting between four and twelve weeks. Researchers examined outcomes related to daily functioning by using specific patient questionnaires and monitored patient reports of success regarding sexual attempts.

The studies reported on the changes measured in patient-reported scores and event logs between the groups receiving the compound and the groups receiving the placebo. The results apply only to the populations studied, as initial trials often excluded individuals with severe heart conditions, meaning evidence for this particular subgroup is still emerging.

Evidence Summary for Pulmonary Arterial Hypertension (PAH) Studies

Sildenafil Citrate was evaluated in patients with Pulmonary Arterial Hypertension (PAH), a condition associated with physiological strain. Research relied on randomized, controlled trials and systematic meta-analyses.

The primary outcomes that researchers examined related to systemic or functional imbalance, including functional capacity, measured by the 6-Minute Walk Distance (6MWD) test. Researchers monitored a composite outcome called Time to Clinical Worsening (TTCW), which tracks significant health events. The studies described patterns where changes in these measurements were observed over the typical 12 to 16-week study periods.

Long-Term Studies and Follow-up Duration

For both ED and PAH, the foundational evidence comes from studies observing responses over relatively short time intervals. To gather data on continued use, trials were followed by open-label extension studies, where patients were observed in settings lasting for periods of up to three years. Comprehensive, long-term effects are not fully established or well-characterized by controlled research beyond this duration.

What is Still Uncertain About Silagra Evidence

Comparative evidence is lacking from large head-to-head trials directly comparing Sildenafil Citrate to other medications in the same class. Furthermore, most PAH trials were not designed to detect differences in all-cause mortality as a primary measure. Finally, much of the ED research is based on patient-reported outcomes (PROs), which contribute to the broader evidence landscape with an inherent variability that may differ from person to person.

Common questions about Silagra (FAQ)

Q: Do women ever use Silagra, and what are the effects described?

Official product information confirms that Sildenafil is approved to treat Pulmonary Arterial Hypertension (PAH) in both adult men and women. However, for the treatment of erectile dysfunction (ED), the medication is not indicated for use by women. This means the ED indication is reserved for adult men, as defined by regulatory documents.

Q: What is the general success rate mentioned in clinical trials for Silagra?

Studies detailed in the official product information for erectile dysfunction (ED) report that approximately 69% of attempts at sexual intercourse were successful for men receiving the medicine. For comparison, success was reported in 22% of attempts for those receiving a placebo. It is noted that individual responses and efficacy rates may vary depending on the patient subgroup studied.

Q: Can a user take Silagra if they have had a stroke in the past?

Official safety warnings caution against or strictly prohibit use in patients who have suffered a stroke within the last 6 months. The current regulatory labels do not offer specific guidance regarding the risks for a stroke that occurred significantly longer than six months ago. Such circumstances typically require individual evaluation by a healthcare provider.

Q: What is the key difference between the brand name and the generic form of Silagra's active ingredient?

According to regulatory standards, the generic form of Sildenafil Citrate is required to be bioequivalent to the original brand-name product. This means the generic is expected to work in the body in the exact same way. Therefore, the therapeutic effect is expected to be the same as the branded medicine, based on regulatory criteria.

Q: Can taking grapefruit juice affect the way Silagra works in the body?

Studies show that consuming grapefruit juice may affect the way Silagra is processed by the body. This is because grapefruit juice is known to inhibit the CYP3A4 enzyme, which is responsible for breaking down the medicine. This process can result in elevated plasma concentrations of Sildenafil, which may increase the likelihood of experiencing side effects.

Q: How long does the effect of Silagra usually last in the body?

Clinical information referenced in official documents indicates that the effects of sildenafil may be maintained for a duration of up to 12 hours in some users. While the most pronounced effects typically occur earlier, this timeframe is noted in pharmacokinetic data.

Q: Is Silagra suitable for people who have diabetes?

Official studies have examined the use of sildenafil for erectile dysfunction in specific patient populations, including those with type 2 diabetes mellitus. Research indicates that the medicine has demonstrated effectiveness and a generally acceptable safety profile for ED within this patient group.

Q: Does alcohol interact negatively with Silagra?

The official product information notes that alcohol may potentiate or increase the blood pressure-lowering effects of sildenafil. This can lead to symptoms such as dizziness, headaches, or even fainting. Due to this potential interaction, patients are generally advised to discuss alcohol consumption with their prescribing physician.

Q: Can taking Silagra cause a person to feel dizzy?

According to official patient information provided by regulatory bodies, dizziness is listed as one of the documented common side effects of Sildenafil Citrate tablets.

Q: Does Silagra have any known interactions with herbal supplements?

Regulatory guidance notes that herbal remedies and supplements are generally not subject to the same rigorous testing as prescription medications. For this reason, official guidance suggests patients discuss all herbal products and supplements being used with a healthcare provider.

Q: Is Silagra a controlled substance or scheduled drug?

Official regulatory classification indicates that sildenafil is generally not classified as a controlled substance. It is not currently listed on any schedule by the Drug Enforcement Administration (DEA).

Q: Is it possible to become dependent on Silagra?

Regulatory documents state that sildenafil is not physically addictive and is not associated with physical dependence or withdrawal symptoms. However, official reports have noted instances of psychological dependence associated with the non-medical use of the medicine.

Q: Are there any restrictions on driving or operating machinery after taking Silagra?

The official Summary of Product Characteristics advises caution because sildenafil can cause side effects like dizziness and changes in vision. Because of this, individuals should monitor their response to the medication before engaging in activities that require full attention.

Q: Is it normal for a user to feel muscle aches or back pain while on Silagra?

Official patient information confirms that back pain and muscle pain are listed among the common side effects of the active ingredient sildenafil. This information is based on clinical trial data reported to regulatory bodies.

The storage and disposal of Silagra (sildenafil tablets) must follow specific conditions detailed in official regulatory labeling.

Item	Official Regulatory Statement
Labeled Storage Temperature	Store at controlled room temperature, specifically 20 C to 25 C (68 F to 77 F) [FDA Label].
Protection Requirements	Keep in a dry place, away from excess heat and moisture [MedlinePlus].
Container Rules	Must be kept in the original container and be tightly closed [MedlinePlus].
Child-Protection Storage	Keep the medication out of the reach of children [FDA Label].
Disposal Instructions	Unused or expired tablets should be disposed of through a drug take-back program or by following FDA household trash disposal guidelines (mixing with an unappealing substance) [FDA Disposal Guidance]. Do not flush down the toilet, as sildenafil is not on the list of medicines recommended for flushing [FDA Flush List].